Welcome to our dedicated page for TENAX THERAPEUTICS SEC filings (Ticker: TENX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenax Therapeutics filings document a Phase 3, development-stage pharmaceutical company developing cardiopulmonary therapies, including TNX-103 (oral levosimendan) for PH-HFpEF. Recent 8-K reports record financial results, clinical program updates for LEVEL and LEVEL-2, intellectual-property notices, and amendments to levosimendan license rights, including expanded worldwide rights for orally administered products.
Proxy and current-report filings also describe Nasdaq-listed common stock, executive appointments, employment and compensation arrangements, equity awards, governance matters, and named-executive pay disclosures. These records frame the company's capital structure, leadership responsibilities, material agreements, and clinical-stage operations around levosimendan development and commercialization rights.
Tenax Therapeutics, Inc. received an updated ownership report from Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander via Amendment No. 1 to a Schedule 13G. The reporting group discloses beneficial ownership of 876,230 shares of Tenax common stock, representing 3.3% of the class.
The shares are reported with shared voting and dispositive power and no sole voting or dispositive power. The filing notes that the securities are held by entities over which the Millennium entities and Mr. Englander have voting control and investment discretion, and it states that this should not, by itself, be construed as an admission of beneficial ownership. The group confirms ownership of 5 percent or less of the class.
Tenax Therapeutics, Inc. CEO Christopher Thomas Giordano exercised stock options on July 13, 2026 to acquire 8,719 common shares, including 8,500 shares at $5.94 per share and 219 shares at $3.549 per share. The aggregate exercise price for these options was paid in cash.
After the exercises, he directly owned 11,324 and 2,824 common shares in the reported accounts and continued to hold stock options covering 1,400,000 shares at a $5.89 exercise price and 450,000 shares at a $13.30 exercise price, with vesting schedules extending over several years and expirations in 2035 and 2036.
TENAX THERAPEUTICS INC reports that FMR LLC beneficially owns 3,942,373 shares of Common Stock, representing 14.9% of the class as of 06/30/2026. The filing states the shares are held with sole dispositive power and identifies Abigail P. Johnson in a related capacity.
Tenax Therapeutics, Inc. filed an update stating that results from its Phase 3 LEVEL clinical trial of TNX-103 (oral levosimendan) in pulmonary hypertension in heart failure with preserved ejection fraction will be presented in a Late-Breaking Clinical Science session at the European Society of Cardiology Congress 2026 in Munich.
The company now plans to report topline LEVEL data in August 2026 and is moving toward database lock and statistical analysis in the coming weeks. The registrational trial enrolled over 230 patients in the United States and Canada and is powered at well over 90% to detect a 25-meter change in 6-minute walk distance, its primary endpoint.
Tenax Therapeutics, Inc. entered into a new Supply Agreement with Orion Corporation giving Orion responsibility for manufacturing and supplying Tenax’s orally administered levosimendan product for development and, if approved, commercial use. The agreement covers forecasting, ordering, delivery, pricing, quality and cost-sharing for manufacturing scale-up.
The Supply Agreement runs for an initial five-year term from first delivery of product, with automatic three-year renewals unless either party gives 24 months’ written notice. It may be terminated for material breach after a 60-day cure period, insolvency or termination of the related License Agreement.
Concurrently, Tenax and Orion signed a Sixth Amendment to their existing License Agreement. This extends to December 31, 2035 the deadline to obtain U.S. regulatory approval for the product before a termination right based on missing that milestone becomes effective and adds information and cybersecurity requirements for Tenax, while leaving other license terms unchanged.
Tenax Therapeutics updated its executive employment agreements and adopted new company-wide severance and change in control plans. The Board approved amendments for Christopher Giordano, Thomas Staab, and Stuart Rich that align their severance and equity vesting protections with the new plans.
Outside a change in control, each executive may receive 12 months of base salary plus up to 12 additional months based on tenure, a pro-rated target bonus, and 12 months of COBRA reimbursements, with full equity acceleration for Dr. Rich. If a qualifying termination occurs from three months before to 12 months after a change in control, Mr. Giordano can receive 18 months of salary and COBRA reimbursements, while all three receive at least 12 months of salary, a full target bonus, and accelerated vesting.
The company also adopted a Change in Control Plan offering double-trigger equity acceleration and cash severance, and a Severance Plan for terminations without cause, both for eligible employees other than executive officers and conditioned on a release of claims.
T. Rowe Price Associates files an amended Schedule 13G reporting beneficial ownership of 586,990 shares of Tenax Therapeutics common stock. The filing states this represents 2.2% of the class and lists sole voting and sole dispositive power over those shares. The cover shows 05/31/2026 and the amendment is signed on 06/05/2026.
The filing is marked under the heading "Ownership of 5 Percent or Less of a Class," and includes a statement denying that the filer is the beneficial owner. No transaction price, acquisition date, or purchase method is disclosed in the excerpt.
Tenax Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders held on June 2, 2026. Stockholders elected seven directors, including June Almenoff, Michael Davidson, Declan Doogan, Christopher T. Giordano, Robyn M. Hunter, Gerald T. Proehl, and Stuart Rich, each to serve a one-year term expiring in 2027.
Each director nominee received between 15,762,162 and 17,397,413 votes in favor, with additional withheld votes and 3,742,678 broker non-votes recorded for each. Stockholders also ratified the appointment of Cherry Bekaert LLP as the company’s independent registered public accounting firm for the year ending December 31, 2026, with 21,304,543 votes for, 3,688 against, and 11,073 abstentions.
Tenax Therapeutics Schedule 13G shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 1,347,130 shares of Tenax common stock, representing 5.1% of the class as of 05/18/2026.
The filing states these shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers. The filing is a joint statement and is signed by the reporting parties on 05/19/2026.
Tenax Therapeutics, Inc. reports that Logos Global Management and related reporting persons jointly disclose beneficial ownership of 800,000 shares of Common Stock, representing 3.0% of the class based on 26,525,159 shares outstanding as of May 8, 2026. The filing states shared voting and dispositive power for the 800,000 shares and is signed by William Arsani on behalf of the reporting persons on 05/15/2026.